Haesuk Park, Ph.D.

Haesuk Park

Assistant Professor

Pharmaceutical Outcomes and Policies

OFFICE: HPNP Room 3325

EMAIL: hpark@cop.ufl.edu

PHONE: 352-273-6261

CV: Link to CV

 

Education

  • B.S. Pharmacy, Chung-Ang University, Seoul, South Korea
  • M.S. Pharmacy, Chung-Ang University, Seoul, South Korea
  • Ph.D. University of Texas at Austin

Research Interests

Pharmacoeconomics and health policy research
Economic and health outcomes evaluation
Meta-analysis

Biographical Sketch

Haesuk Park, Ph.D., is an Assistant Professor in the Department of Pharmaceutical Outcomes and Policy. She received her Bachelor and Master in Pharmacy from South Korea, and her Ph.D. at The University of Texas at Austin, College of Pharmacy, Health Outcomes & Pharmacy Practice. Her research centers on economic and health outcomes studies of medications and pharmaceutical care services as well as policy associated with the use of pharmaceuticals. She is passionate about investigating questions related to health policy in vulnerable populations and, particularly, how a policy affects access to care, the quality and cost of health care, and ultimately health outcomes. In recent years, the clinical focus of her research has centered on patients with hepatitis C virus (HCV) infection, a research area with growing intensity and breadth due to the increasing awareness of the disease burden and the continuing development of new treatments. In 2018, Park received a 5-year NIH/National Institute on Drug Abuse (NIDA) K01 to build a research program in the area of HCV and health policy for individuals with substance use disorders.  Currently, she also collaborated on a NIH/NHLBI R01 project to evaluate the impact of the pharmacist-led telehealthcare medication therapy management to change health outcomes in adolescents and young adults with asthma (MATCH).

Her research has received a number of awards and recognition by the professional community such as the Best New Investigator Presentation Award at the International Society for Pharmaceutical Outcomes Research (ISPOR), Best Paper Award in the Economic, Social & Administrative Sciences at the American Pharmacists Association (APhA) Annual Meeting, and the 2015 University of Florida Excellence Award for Assistant Professors.

Recent Publications

Park H, Wang W (g), Henry L, Nelson D. Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C virus-infected patients in the U.S. Hepatology 2018 [In Press]

Dawwas G (g), Smith S, Park H. Cardiovascular outcomes of sodium glucose cotransporter-2 in patients with Type 2 diabetes. Diabetes, Obesity and Metabolism 2018. DOI: 10.1111/dom.13477

Dawwas G (g), Steve S, Park H. Risk of heart failure  hospitalization among users of Dipeptidyl Peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists. Cardiovascular Diabetology 2018. DOI: 10.1186/s12933-018-0746-4

Park H, Jeong D, Nguyen P, Henry L, Hoang J, Kim Y, Sheen E, Nguyen M. Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis. PlosOne 2018; 13(4): e0196452

Park H, Chen C, Henry L, Wang W, Cook R, Nelson D. Hepatitis C Virus Infection Increases the Risk of Chronic Kidney Disease (CKD) while Effective HCV Treatment Decreases the Incidence of CKD. Hepatology 2017 DOI: 10.1002/hep.29505 *Selected for editorial highlights.

Xinyi J (g), Xiao H, Segal R, Mobley W, Park H. Trends in readmission rates, hospital charges and mortality for patients with chronic obstructive pulmonary disease (COPD) in Florida from 2009-2014. Clinical Therapeutics 2018; 40(4): 613-626

Park H, Adeyemi A (p), Wang W (g), Roane T. Impact of a telephonic outreach program on medication adherence in Medicare Prescription Drug (MAPD) Plan beneficiaries in Florida. Journal of the American Pharmacist Association (JAPHA) 2017; 57(1):62-66

Younossi Z, Park H, Dieterich D, Saab S, Ahmed A, Gordon S. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all oral regimes good value to society? Liver International 2017;37(5):662-668

Younossi Z, Park H, Ahmed A, Gordon S, Fergusong J, Dieterich D, Saab S. Real-worl outcomes of ledipasvir/sofosbuvir in treatment-naïve patients with hepatitis C. American Journal of Managed Care 2016;22(5):SP205-SP211

Younossi Z, Park H, Henry L, Adeyemi A (p), Stepanova M. The extra-hepatic manifestations of hepatitis C – a meta-analysis of prevalence rates, effects o patient-reported outcomes economic burden. Gastroenterology 2016;150(7):1599-608

 

Full list of published work retrievable by PubMed: http://www.ncbi.nlm.nih.gov/sites/myncbi/1Fi2ensYbNxQd/bibliograpahy/40314061/public/?sort=date&direction=descending

You may also wish to check out Dr. Park’s ResearchGate and Google Scholar pages